Loading
A phase 1/2 trial of EG-70 (phase 1) in bladder & urothelial cancer, run by enGene, Inc., now recruiting.
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve is a phase 1/2 interventional study registered as NCT04752722 by enGene, Inc., with 350 participants planned, started 2021-04-22 and due to reach its primary completion in 2028-04-30. Interventions recorded: EG-70 (phase 1), EG-70 (phase 2) Master Protocol and Surfactant Bladder Pre-Rinse and EG-70 (Substudy).
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.